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Anticoagulant prophylaxisBackground: Integrin β3 is involved in tumor and endothelial cell biology aswell as in platelet aggregation. Here-
in, we evaluated the predictive potential of three germline single nucleotide polymorphisms (SNPs) in the
integrin β3 gene (rs3809865, rs5918 and rs4642) to predict the risk of venous thromboembolism (VTE) in colo-
rectal cancer (CRC) patients, which is one of the leading causes of death among cancer patients.
Methods: 112 patients diagnosed with CRC enrolled in the prospective Vienna Cancer and Thrombosis Study
(CATS) were assessed with a median follow-up of 46 months. DNA was isolated from venous blood samples
and SNPs were analyzed by the PCR-RFLP method.
Results: VTE occurred in 12% (n= 13) of all patients. The SNPs rs5918 and rs4642 were not associated with VTE
risk. For rs3809565, 23% (n= 11) of patients had the A/A genotype, 4% (n= 2) had the A/T genotype, but none
(0%) had the T/T genotype. In the univariate analysis, patients with the A/A genotype had a signiﬁcantly higher
risk to develop VTE compared to the other polymorphisms (P=0.0005 after Fine and Gray). In themultivariable
analysis, the predictive value remained signiﬁcant.
Conclusions: This study identiﬁed the rs3809865 A/A genotype as an independent risk factor for VTE in CRC pa-
tients. Our ﬁndings would help identify high risk patients and would be essential for tailored anticoagulant
prophylaxis.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Venous thromboembolism (VTE) is one of the leading causes of
death in cancer patients causing additional life-threatening complica-
tions and signiﬁcantly higher health care costs [1–3]. Speciﬁc cancer re-
lated patient characteristics such as tumor site, stage at diagnosis,
histologic subtype, tumor grade or anticancer treatment with
ﬂuoropyrimidines ± bevacizumab or oxaliplatin can promote the de-
velopment of VTE [4–8]. In colorectal cancer (CRC) patients the estimat-
ed risk of developing VTE within 2 years was reported to be 8.2% [9].
Patients with metastatic disease have a 5- to 13-fold higher risk of de-
veloping VTE compared to those with localized disease [10,11]. TheTE, venous thromboembolism;
olymorphism.
er Vienna,Medical University of
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is complex and is mediated by various interactions of tumor cells with
platelets and endothelial cells, affecting the clotting system [12,13].
Integrin receptors are heterodimeric cell adhesion proteins which
consists of an α and β subunit [14]. Integrin β3 is essentially expressed
on endothelial cells, platelets, osteoclasts and hematopoietic cells and
corresponds to the group of integrins that binds to proteins containing
the arginine-glycine-aspartic acid (RGD)-motif [15]. Integrin β3 can
form heterodimers with the subunits αV and αIIb. Integrin αVβ3 is
expressed by activated endothelial cells and tumor cells [16]. It pro-
motes proangiogenic endothelial cell behavior, such as cell migration,
invasion and survival, and is a major mediator of tumor angiogenesis,
tumor growth and platelet aggregation [16–20]. Integrin αIIbβ3 is ex-
clusively expressed on platelets and mediates platelet aggregation to
promote thrombus formation [20,21].
The paramount role of integrin β3 in thrombus formation prompted
us to investigate if there was a correlation between VTE in patients with
CRC and the β3 integrin SNPs rs3809865, rs5918 and rs4642. The selec-
tion of these SNPs is based on a previous work [22], in which it wasthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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genes could predict stage-speciﬁc time to tumor recurrence in colon
cancer. In this post-hoc analysis, we retrospectively analyzed 112 pa-
tients recruited in the framework of the prospective Vienna Cancer
and Thrombosis Study (CATS) for association of genetic variants in the
integrin β3 gene with risk of VTE. 43% (n = 48) of all the patients had
a rs3809865 A/A genotype, 45% (n = 50) a A/T genotype and 12%
(n = 14) a T/T genotype. VTE occurred in 12% (n = 13) of all patients,
23% (n = 11) of A/A rs3809865 patients, in 4% (n = 2) of A/T patients,
but none (0%) patients had the T/T rs3809865 genotype. rs5918 and
rs4642 SNPs were not associated with risk of VTE in this population.
This study identiﬁed the germline polymorphism A/A of rs3809865 as
an independent risk factor for VTE in CRC patients. A single laboratory
test stratifying high and low risk groups for developing VTE, could
lead to prevention strategies, thus, improving quality of life, safe costs
and decreasing mortality rates in these patients.
2. Methods
2.1. Patients and study design
112 CRC patients who entered the prospective CATS between Febru-
ary 2004 and June 2011 were analyzed. The studywas performed in ac-
cordance with the Declaration of Helsinki and was approved by the
ethical committee of the institution. Detailed information about the
CATS study has been reported previously [23,24]. In brief, patients diag-
nosed with CRC gave informed consent before venous blood samples
were drawn. The overall aimof CATSwas deﬁned to identify parameters
and biomarkers to predict occurrence of VTE in cancer patients. While
the CATSmaximumobservation period for VTE events is 2 years, the oc-
currence of objectively conﬁrmed VTE in this analysis was retrospec-
tively extended until August 2013. In CATS, study patients were not
routinely screened for VTE, but symptomatic or fatal VTEwere classiﬁed
as events. Diagnosis of VTEwas in all cases conﬁrmed by objectivemed-
ical imaging methods, such as duplex sonography or computer tomo-
graphic scans. Each event was discussed and evaluated by an
independent adjudication committee. Non symptomatic events, such
as accidentally detected VTE in a restaging examination, were
considered as an event when the adjudication committee considered
them to be of clinical signiﬁcance. Patients with continuous oral
anticoagulation were excluded and no routine thromboprophylaxis for
VTE was performed in our study. However, thromboprophylaxis with
low-molecular-weight-heparin (LMWH) was allowed in hospitalized
patients or after surgery according to clinical practice guidelines. In ad-
dition to CATS, this analysis considered additional patient data such as
anti-VEGF treatment.
2.2. Blood sampling and SNP genotyping
Venous blood samples were drawn into plasma vacuum tubes
(Vacuette; Greiner Bio One, Austria) containing one-tenth volume sodi-
um citrate stock solution at 0.129 mM. To obtain platelet-poor plasma,
the citrated blood was centrifuged (ROTANTA/TRC; Hettich, Germany)
at 1500 g for 15 minutes, and to obtain platelet free plasma a second
centrifugation step (Eppendorf) at 13 400 g for 2 minutes was per-
formed. Plasma aliquots were stored at−80 °C until they were assayed
for PCR testing of three SNPs in integrin β3 gene. Samples were coded
before laboratory analysis. During analysis researchers and technicians
were unaware of the patients’ characteristics at all times. Genotyping
was performed applying a combined PCR-restriction fragment length
polymorphism approach (PCR-RFLP). In brief, a short sequence includ-
ing the site in question was ampliﬁed using primers binding
66–99 bps upstream and downstream resulting in PCR products
149–158 bps in size. Subsequently, the ampliﬁcation product was
digested using restriction enzymes, which were speciﬁcally chosen to
cut or not at the site of the polymorphism in question according togenotype. After digestion, the resulting DNA-fragments were separated
on an agarose gel. Consequently, lanes with bands in all three size
ranges were considered heterozygote samples and lanes with only
one band in the 150 bp region or two bands in the 60–100 bp region
were considered to be homozygote in respect to the SNP in question.
(Primers and enzymes are listed in supplemental Table S1). PCR assays
were performed with 1.25 U DreamTaq™, 8 mM (total) dNTPs, 1x
DreamTaq™ Green Buffer (Fermentas), 0.5 μM fw-primer and 0.5 μM
rv-primer. Annealing temperatures were optimized in advance. Restric-
tion digestions with SNP-speciﬁc restriction enzymes were performed
according to the recommendations of the manufacturer. DNA-
fragments were separated on a pre-stained (GelRED™, GenON) 4% aga-
rose gel at 120 V for 30 min. and visualized on a BioRADChemiDOC XRS
system.
2.3. Statistical analysis
Continuous variables were described with median and interquartile
range (IQR); nominal variables were described by absolute numbers
and percentage. SP-Selectin was compared between genotypes using
t-tests on the logarithmised variable. The median follow-up time was
estimated using the reverse Kaplan-Meier method [25]. The effects of
sex, age, stage, metastatic site, tumor location, BMI and of the polymor-
phisms rs3809865, rs5918 and rs4642 on the occurrence of VTEwas in-
vestigated in univariate, bias corrected Fine-Gray models [26] where
death was considered as competing event. Due to the small number of
events, we only considered multivariable Fine-Gray models including
rs389086 and either sex, age, stage, metastatic site, tumor location
and BMI. Since Fine-Gray models with death as competing risk do not
handle time-dependent variables adequately [27], the effect of the
time-dependent variable treatment with bevacizumab and of
rs3809865 adjusted for treatment with bevacizumab was estimated in
a bias corrected Cox-model where death was considered as censoring
event. Here, we assumed that the effect of bevacizumab persisted
4 weeks after the end of therapy. We plotted crude cumulative inci-
dence curves for each level of the polymorphism rs3809865, where
death was considered as competing event. Chi-square goodness-of-ﬁt
tests were used to test the polymorphisms for Hardy-Weinberg Equilib-
rium and to compare for each polymorphism theminor allele frequency
of our study population with the Global MAF based on 1000 Genomes.
All analyses were carried out using SAS version 9.3 (SAS Institute Inc.,
Cary, NC, USA).
3. Results
3.1. Study population
Baseline demographic and clinical characteristics of the study
population are displayed in Table 1. One-hundred-twelve patients
after diagnosis with CRC were prospectively observed. Median age
at time of enrolment into CATS was 64 years (IQR, 57–71 years). Me-
dian observation time was 1399 days (IQR, 704–2197 days). 42 fe-
male patients (37%) and 70 male patients (63%) had been enrolled.
Left sided primary tumors, including those originating from the
splenic ﬂexure, sigmoid, rectosigmoid junction, or rectum were re-
corded in 81 cases (72%), while right sided colon cancer was listed
in 23 cases (21%). 3 patients (2%) were enrolled with two colorectal
primary tumors and 5 (4%) patients were considered as CRC with
non-recorded primary origin. Most patients (79%) had locally ad-
vanced (stage III) or metastatic disease (stage IV). During the obser-
vation period, 49 patients (44%) received the anti-VEGF antibody
bevacizumab. Two patients were enrolled into blinded randomized
controlled studies considering bevacizumab as the experimental
treatment arm. Whether the two patients received bevacizumab is
unknown; none of these patients, however, were diagnosed with
VTE.
Table 1
Baseline characteristics of the study population (n = 112).
Characteristic Value Percentage
Median age at study entry (years) 64
IQR 57-71
Sex
Female 42 37%
Male 70 63%
Site of the primary tumor
Rectum 50 45%
Rectosigmoid junction 2 1.8%
Sigmoid colon 25 22%
Splenic ﬂexure 4 3.6%
Transverse colon 6 5.4%
Hepatic ﬂexure 1 0.9%
Ascending colon 7 6.3%
Cecum 8 7.1%
Appendix 1 0.9%
Two sites 3 2.7%
Unknown 5 4.5%
Tumor stage at study entry⁎
Stage 0 3 2.7%
Stage I 9 8%
Stage II 11 9.8%
Stage III 17 15%
Stage IV 72 64%
Progression of tumor at study entry
Localized 40 36%
Distant metastasis 72 64%
Anti-VEGF-A treatment from study entry
Bevacizumab treatment 49 44%
Study patient optional bevacizumab treatment 2 1.8%
Categorical variables are described with absolute numbers and percentages. Age is de-
scribed as median with IQR.
⁎ For staging UICC stagingwas used (stage Ia and Ib are summarized as stage I; stage 0 is
deﬁned as ypT0pN0M0, R0 - these are patients with rectum carcinoma, who received
presurgical radiotherapy).
Table 2
Baseline characteristics of VTE patients (N= 13; 11.6%).
Characteristic Value Percentage
Median age at study entry (years) 67
IQR 62-71
Sex
Female 2 15%
Male 11 85%
Site of cancer
Rectum 6 46%
Rectosigmoid junction 0 0
Sigmoid colon 2 15%
Splenic ﬂexure 1 7.7%
Transverse colon 1 7.7%
Hepatic ﬂexure 0 0
Ascending colon 1 7.7%
Cecum 2 0,15
Appendix 0 0
Two sites 0 0
Unknown 0 0
Tumor stage at study entry
Stage 0 0 0
Stage I 1 7.7%
Stage II 1 7.7%
Stage III 3 23%
Stage IV 8 62%
Progression of tumor at study entry*
Localized 5 38%
Distant metastasis 8 62%
Tumor stage when VTE occurred
Stage 0 0 0%
Stage I 0 0%
Stage II 0 0%
Stage III 2 15%
Stage IV 11 85%
Anti-VEGF-A treatment and VTE
Bevacizumab at time of VTE (+4 weeks) 4 31%
In relation to total population with bevacizumab 4 8.2%
Site of thrombotic event counted
Isolated pulmonary vein thrombosis (PE) 6 46%
Isolated deep vein thrombosis (DVT) 6 46%
Subclavian vein thrombosis (PAC-implant) 1 7.7%
Categorical variables are described with absolute numbers and percentages. Age is de-
scribed as median with IQR. *For staging UICC staging was used (stage Ia and Ib are sum-
marized as stage I; stage 0 is deﬁned as ypT0pN0M0, R0 - these are patients with rectum
carcinoma, who received presurgical radiotherapy).
Table 3
Subdistribution hazard ratio for A/A compared to A/T and T/T at rs3809865 (adjusted for
either sex, age, stage, metastatic sites, tumor location, BMI or bevacizumab containing
treatment).
Factors HR 95% CI P
Parameters analyzed
Unadjusted 7.87 2.31–40.00 0.0005
Adj. for sex 7.52 2.20–38.46 0.0008
Adj. for age 7.63 2.23–40.00 0.0007
Adj. for stage *1 13.89 3.56–76.92 b .0001
Adj. for metastatic sites 12.08 3.42–66.67 b .0001
Adj. for tumor location*2 7.7 2.26–40 0.0006
Adj. for BMI 8.62 2.52–45.45 0.0003
Adj. for bevacizumab*3 8.20 2.31–41.67 0.0006
*1Stagewas determined at CATS admission date. Stagewas categorized in stage 1–3 and 4,
3 patients (stage 0) were excluded from analysis.
*2Three patients with two-sided tumor location were excluded from analysis.
*3Study patients with unsure treatment of bevacizumabwere excluded from the analysis.
867D. Bianconi et al. / Thrombosis Research 136 (2015) 865–8693.2. Thromboembolic events
VTE occurred in 12% (n = 13) of patients, 38% (n = 5) were diag-
nosed with stage III and 62% (n = 8) with distant metastatic disease
(stage IV). Detailed information on patients with VTE is given in
Table 2. 11 patients were male (85%). 9/13 (69%) patients had left
sided CRC, while 4/13 (31%) had right sided colon cancer. Of the 49 pa-
tients who received a bevacizumab-containing therapy, four developed
VTE (8%). At the time of VTE event, all patients had either locally ad-
vanced (2/13) or metastatic CRC (11/13). One VTE was associated
with a Port-a-Cath (PAC) implant. By August 2013, 62% (n= 69) of pa-
tients died and 38% (n = 43) were alive.
3.3. Thromboembolic events and rs3809865 distribution
48 (43%) patients presented the homozygous mutant variant of
integrin β3 rs3809865 A/A, 50 patients (45%) were harboring the
A/T and 14 (12%) the T/T genotype. This genotype distribution
obeyed the genotype count reported in the 1000 Genomes panel
(52,91% for the A/A variant, 38,86% for the heterozygote genotype
and 8,22% for the T/T variant) [28]. From the 13/112 patients (12%),
who developed an objectively conﬁrmed VTE, 11 patients (85%)
had an rs3809865 A/A genotype, while 2 (15%) had an A/T genotype.
No VTE patient had a homozygous mutant variant rs3809865 T/T.
3.4. Rs3809865 and the risk of VTE
Investigating the effect of rs3809865 polymorphism on the risk of
VTE in a univariate Fine and Gray analysis with death as competing
event, we found that patients with a rs3809865 A/A genotype had a sig-
niﬁcantly higher risk to develop VTE compared to those with the poly-
morphism A/T or T/T (HR = 7.87; 95% CI: 2.31 to 40.00, p = 0.0005).This effect remained signiﬁcant in the multivariable analysis considering
in addition either sex, age, stage, tumor location (left vs. right), metastatic
sites, BMI or bevacizumab-containing treatment (Table 3). Cumulative in-
cidence of developing VTE within 2500 days was signiﬁcantly higher for
the homozygous mutant variant rs3809865 A/A with 30% compared to
8% for polymorphism A/T or 0% for polymorphism T/T (Fig. 1). Additional
analysis of sP-Selectin and rs3809865 genotype A/A did not show
Fig. 1. Competing RiskModel: Cumulative incidence of VTE stratiﬁed by rs3809865 poly-
morphisms (n = 13). Patients with rs3809865 polymorphism A/A (blue) are on a higher
risk of developing VTE compared to those with polymorphism A/T (red) or T/T (green).
Table 5
rs4642 polymorphism distribution, p = 0.9579 for polymorphism A/A compared to A/G
and G/G.
rs4642 Number of Patients (%) Number of patients with VTE events
A/A 39 (44.32%) 5 (45.45%)
A/G 33 (37.50%) 5 (45.45%)
G/G 16 (18.18%) 1 (9.09%)
868 D. Bianconi et al. / Thrombosis Research 136 (2015) 865–869signiﬁcantly increased sP-Selectin levels in this subgroup of patients (p=
0.6063). Neither sex, age, stage, tumor location, metastatic sites, BMI nor
bevacizumab-containing treatment showed a signiﬁcant associationwith
VTE occurrence in univariate analysis.
3.5. Integrin β3 rs5918 or rs4642 and VTE in CRC
DNA of 96 CRC patients, among them DNA from all 13 patients with
VTE, was assessable for further SNP germline polymorphism analysis.
Integrin β3 rs5918 C N T had no predictive value for VTE (p = 0.2466)
(Table 4). Integrin β3 rs4642 polymorphism, which could be analyzed
in 88 patients, also did not reveal a signiﬁcant association with the
risk of developing VTE (A/A compared to A/G and G/G, p = 0.9579)
(Table 5).
4. Discussion
VTE contributes to elevated morbidity and mortality in cancer pa-
tients and so far, several risk factors for VTE were identiﬁed in different
clinical studies. It was already shown that the risk of VTE in the cohort of
patients presented herein (CATS) correlates with tumor stage, metasta-
tic sites, tumor location and chemotherapy (reviewed in [29]). There
was no association found between risk of VTE and age, gender or BMI,
which is in line with other clinical studies [30,31]. In the present study
we observed an almost 8-fold increased risk of VTE in CRC patients car-
rying the A/A genotype of integrin β3 rs3809865. Of the 112 patients el-
igible for SNP analysis and VTE risk assessment, almost one quarter of
the 48 patients with rs3809865 polymorphism A/A, only 4% of the 50
patients with polymorphismA/T and none of the 14 patients with poly-
morphism T/T developed VTE during the observation period. In multi-
variable analysis adjusting for either sex, age, stage tumor location
(left vs. right), metastatic sites, BMI or treatment with bevacizumab
the predictive value remained signiﬁcant. The allele frequencies of
rs3809865 in our study population did not show a signiﬁcant deviation
from the Hardy-Weinberg Equilibrium (supplemental Table S2).Table 4
rs5918 polymorphism distribution, p = 0.2466 for polymorphism T/T compared to C/T
and C/C.
rs5918 Number of Patients (%) Number of patients with VTE events
T/T 75 (78.13%) 12 (92.31%)
C/T 18 (18.75%) 1 (7.69%)
C/C 3 (3.13%) 0 (0%)These results indicate that the hitherto unknown integrin β3 single
nucleotide polymorphism rs3809865 can predict the risk of VTE in
CRC patients. rs3809865 is located at the 3´UTR region of the integrin
β3 gene. The 3´UTR region regulates β3 integrin gene expression and
regulation at the mRNA level and interacts with miRNAs [32]. Thus, al-
though not shown here, it is tempting to speculate that rs3809865
might functionally affect miRNA binding and consequently, the protein
expression level of the integrin β3 subunit [33–35]. In this context, it
was shown before that the miRNAs hsa-mir-506 and hsa-mir-124
bind more stably to the T allele when compared to the A allele of
rs3809865 [35], whichmight lead to an increased expression of integrin
β3 in patients harboring the A/A genotype when compared to those
with an A/T or T/T rs3809865 genotype [35]. Whether rs3809865 mu-
tant variants, which have been described before to affect miRNA inter-
action and integrin β3 expression, have a functional impact on platelet
or endothelial cell activation is so far unknown and is currently investi-
gated in a subsequent study.
Ligand binding to integrin αIIbβ3 mediates stable platelet adhesion,
platelet aggregation, and thrombus formation via binding its ligands ﬁ-
brinogen, von Willebrand factor, and other RGD-sequence containing
matrix proteins. Furthermore, ligand binding triggers an “outside-in”
signaling, resulting in platelet spreading, additional granule secretion,
stabilization of platelet adhesion, platelet aggregation and clot
retraction.
Further on, integrin activation is tightly regulated via intracellular
signaling events (inside-out). Talin binds to the cytoplasmic tail of the
beta integrin subunit [36], which leads to a conformational change of
integrins from an inactive bend formation to an open straighten confor-
mation, which unencrypt the ligand binding site [37–40]. The latter
event is a major regulator for platelet activation and aggregation [20].
A decreased expression of integrin αIIbβ3 is associated with an
increased bleeding risk and is a characteristic of Glanzmann´s
thrombasthenia [41]. Targeting integrinαIIbβ3 affects platelet aggrega-
tion [42] and themonoclonal antibody abciximab (a IIb receptor antag-
onist) is in clinical use during percutaneous coronary intervention for
the prevention of cardiac ischemic complications [43]. Although not
shown here, this large body of evidence suggests that a miRNA binding
site genetic polymorphismmight affectβ3 integrin expression, interfer-
ing with platelet activation.
Patients with advanced disease are on higher risk to develop VTE
[10,11]. At study entrymore than 80% of CRC patients had advanced dis-
ease stages (either stage III or IV). In themultivariable analysis, howev-
er, tumor stage did not affect the predictive value of rs3809865 mutant
variants for risk of VTE.
The detection of new predictive biomarkers for VTE risk assessment
could be an important step forward the improvement in quality of life
and overall survival in cancer patients [1–3,44]. Current risk assessment
models are based on the testing of multiple blood parameters and clin-
ical risk factors [45–47]. The hypercoagulable state in cancer patients
has a complex pathogenesis. A single laboratory parameter with a
high predictive value could improve current risk assessment models.
Our data provide ﬁrst evidence that germline variant integrin β3
rs3809865might predict the risk of VTE in CRC patients. This ﬁrst obser-
vation is currently being validated in an independent prospective
translational study PASSION-ATE (NCT02119026), which analyzes bio-
markers inmetastasized CRC patients during ﬁrst and second line treat-
mentwith bevacizumab and capecitabine plus oxaliplatin or irinotecan.
869D. Bianconi et al. / Thrombosis Research 136 (2015) 865–869In summary, we have shown that a single germline variant of a cen-
tral contributormolecule in tumor-, endothelial cell and platelet biology
might play an important role predicting individual risk of VTE in CRC pa-
tients. Because prevention of thromboembolism in cancer patients, es-
pecially when treated in an out-patient setting, is not generally
recommended, identiﬁcation of high risk patients via a reliable parame-
ter would be essential for tailored anticoagulant prophylaxis. This could
reduce VTE rates in high risk patients and avoid unnecessary side-
effects and health care costs of anti-coagulant agents in those patients
who are at low-risk. Furthermore, the association between integrin sub-
unit genetic variants and risk of VTE supports the functional role of
integrins in the pathogenesis of cancer-associated VTE.
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